Method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method
A method for producing protein compositions comprising fibrinogen and fibronectin is disclosed, wherein a fibrinogen and fibronectin-containing starting solution is treated with a precipitating composition which comprises two different components that modify the solubility of fibrinogen and/or fibronectin, so that in a single-step precipitation a precipitate is formed which comprises fibrinogen and fibronectin, and the precipitate formed optionally is further treated by methods known per se.
1. A pharmaceutical preparation comprising fibrinogen at a concentration of at least 70 mg/ml, a fibronectin:fibrinogen ratio from 0.02 to 0.2, a viscosity of 150 cSt at the most at 20° C., and an osmolarity of less than 500 mOsm, wherein the pharmaceutical preparation, after mixing with a thrombin CaCl 2 solution, forms a non-transparent clot of physiological fibrin structure, and wherein the preparation further contains a solubility-improving substance containing a benzene, pyridine, piperidine, pyrimidine, morpholine, pyrrole, imidazole, pyrazole, furan, thiazole, or purin-containing group, wherein the solubility-improving substance is present at a concentration of 150 mM at the most.
2. The pharmaceutical preparation of claim 1 , wherein the viscosity is 99 cSt at the most at 20° C.
3. The pharmaceutical preparation of claim 1 , wherein the osmolarity is less than 400 mOsm.
4. The pharmaceutical preparation of claim 1 , wherein the preparation is in lyophilized, liquid, or in liquid-deep-frozen form.
5. The pharmaceutical preparation of claim 1 , wherein the fibronectin:fibrinogen ratio is from 0.04 to 0.16.
6. The pharmaceutical preparation of claim 1 , wherein the fibronectin:fibrinogen ratio is 0.1.
7. The pharmaceutical preparation of claim 1 , further comprising a substance selected from the group consisting of antibiotics, growth factors, and pain-alleviating substances.
8. A pharmaceutical preparation comprising fibrinogen at a concentration of at least 70 mg/ml, a fibronectin:fibrinogen ratio from 0.02 to 0.2, a viscosity of 99 cSt at the most at 20° C., and an osmolarity of less than 400 mOsm, wherein the pharmaceutical preparation, after mixing with a thrombin CaCl 2 solution, forms a non-transparent clot of physiological fibrin structure, and wherein the preparation further contains a solubility-improving substance containing a benzene, pyridine, piperidine, pyrimidine, morpholine, pyrrole, imidazole, pyrazole, furan, thiazole, or purin-containing group, wherein the solubility-improving substance is present at a concentration of 150 mM at the most.